Pardeep Nijhawan, Chief Executive Officer and a director of Edesa Biotech, Inc. (NASDAQ:EDSA), filed a Form 4 on October 29, 2026, reporting the acquisition of 27,602 restricted share units on October 28, 2026.

Key Highlights

  • Transaction: Nijhawan acquired 27,602 restricted share units (RSUs) on October 28, 2026, at a price of $0, through a grant under the issuer's 2019 Equity Incentive Compensation Plan.
  • Vesting: According to the filing, the RSUs "vested in full upon grant."
  • Salary context: The RSUs represent awards received in lieu of 90% of the reporting person's monthly base salary, reflecting an increase in annual base salary from $357,696 to $657,423, retroactive for the period from July 1, 2026 through October 10, 2026.
  • RSU calculation: The number of RSUs was determined by dividing the salary portion by the 5-day volume weighted average price (VWAP) of the issuer's common shares through October 27, 2026.
  • Direct beneficial ownership: Following the transaction, Nijhawan directly holds 933,595 common shares.
  • Indirect holdings: Nijhawan also holds shares indirectly: 402,702 through Pardeep Nijhawan Medicine Professional Corporation, 32,013 through The Digestive Health Clinic Inc., 53,104 through 1968160 Ontario Inc., and 32,609 through The New Nijhawan Family Trust 2015.

Edesa Biotech CEO Nijhawan's October 2026 RSU Grant Details

According to the Form 4 filing, Pardeep Nijhawan, who serves as Chief Executive Officer, director, and a 10% owner of Edesa Biotech, Inc. (NASDAQ:EDSA), received a grant of 27,602 restricted share units on October 28, 2026. The filing states that these RSUs were issued under the issuer's 2019 Equity Incentive Compensation Plan and "vested in full upon grant," with a transaction price of $0.

The filing explains that the RSUs were awarded in lieu of 90% of the reporting person's monthly base salary otherwise payable in cash. The grant reflects a salary increase from $357,696 to $657,423 annually, retroactive for the period from July 1, 2026 through October 10, 2026. The number of RSUs was calculated by dividing the applicable salary portion by the 5-day VWAP of the issuer's common shares through October 27, 2026.

Following this transaction, Nijhawan directly holds 933,595 common shares. The filing also reports indirect beneficial ownership through several entities: 402,702 shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,013 shares held by The Digestive Health Clinic Inc., and 53,104 shares held by 1968160 Ontario Inc., each of which the filing identifies as wholly owned by Nijhawan. Additionally, 32,609 shares are held by The New Nijhawan Family Trust 2015, of which Nijhawan is identified as a co-trustee. The filing notes that Nijhawan disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest.

What Was Disclosed

Edesa Biotech CEO Pardeep Nijhawan disclosed the acquisition of 27,602 RSUs on October 28, 2026, at $0, granted in lieu of a portion of base salary under the company's 2019 Equity Incentive Compensation Plan, with direct post-transaction holdings of 933,595 common shares.